

Clinical Management and Follow-up of Hypercholesterolemia Among Perinatally HIV-Infected Children Enrolled in the PACTG 219C Study

Denise L. Jacobson, PhD, MPH,* Paige Williams, PhD,† Katherine Tassiopoulos, DSc, MPH,‡ Ann Melvin, MD, MPH,§ Rohan Hazra, MD,|| and John Farley, MD, MPH¶

Background: Hypercholesterolemia is common in perinatally HIV-infected (HIV+) children, but little is known about the clinical course and management in this population.

Methods: We studied HIV+ children in a multisite prospective cohort study (Pediatric AIDS Clinical Trials Group 219C) and considered follow-up for 2 years after development of hypercholesterolemia. We estimated the time and factors associated with resolution of hypercholesterolemia and described changes in antiretroviral regimen and use of lipid-lowering medications. We defined incident hypercholesterolemia as entry total cholesterol (cholesterol) <220 mg/dL and 2 subsequent consecutive cholesterol \geq 220 mg/dL and defined resolution of hypercholesterolemia as 2 consecutive cholesterol <200 mg/dL after incident hypercholesterolemia.

Results: Among 240 incident hypercholesterolemia cases, 81 (34%) had resolution to normal cholesterol within 2 years of follow-up (median follow-up = 1.9 years). The median age of cases was 10.3 years with 54% non-Hispanic black and 53% male. Resolution to normal cholesterol was more likely in children who changed antiretroviral regimen (adjusted hazard ratio = 2.37, 95% confidence interval: 1.45 to 3.88) and who were 13 years and older (aHR = 2.39, 95% confidence interval: 1.33 to 4.27). Types of regimen changes varied greatly, and 15 children began statins.

Conclusion: The majority of children who develop hypercholesterolemia maintain elevated levels over time, potentially placing them at risk for premature cardiovascular morbidity.

Key Words: HIV, children, hypercholesterolemia, antiretroviral therapy, cohort study

(*J Acquir Immune Defic Syndr* 2011;57:413–420)

INTRODUCTION

Dyslipidemia is commonly observed in HIV-infected adults and children. Studies in adults show that lipid abnormalities occur early in HIV infection before initiation of antiretroviral therapy (ART) and are characterized by low levels of total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C).^{1–4} Elevated triglycerides and very-low-density lipoprotein cholesterol are observed later, especially in those with more advanced disease.⁵ In a study of adult male seroconverters, total-C and LDL-C increased moderately soon after initiation of highly active antiretroviral therapy and many subsequently developed elevation of total-C and LDL-C with a low HDL-C.⁴ In other studies, initial improvements in total-C and LDL-C after initiation of antiretroviral (ARV) coincide with restoration of health and a decrease in HIV viral load.^{1–3}

The hyperlipidemia that is widely reported among adults^{6–8} and children^{9–14} on highly active antiretroviral therapy may be partly associated with specific classes of ARVs or individual agents. For example, several studies have reported higher total-C levels among children on protease inhibitors (PIs)^{10,13,15–19} and specifically with ritonavir use.^{10,12,18} In a longitudinal study, HIV-infected children who developed incident hypercholesterolemia were more likely to be receiving boosted or nonboosted PI.²⁰ Children treated with a nonnucleoside reverse transcriptase inhibitor (NNRTI) also had higher total-C^{10,20} in 2 studies and had higher HDL-C levels¹⁵ in another study compared with those not treated with an NNRTI.

As adults and children live longer with HIV, prolonged dyslipidemia may increase the risk of atherosclerotic disease. Thus, there has been much interest in examining whether type of initial therapy or switching ARV may improve lipid profiles and still maintain viral suppression. Switch studies in adults showed improvements in cholesterol with a switch to atazanavir^{21–23} or

Received for publication December 21, 2010; accepted April 28, 2011.

From the *Center for Biostatistics in AIDS Research; Departments of †Biostatistics; ‡Epidemiology, Harvard School of Public Health, Boston, MA; §Department of Pediatrics, University of Washington School of Medicine, Seattle, WA; ||Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD; and ¶Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD. Supported by the Statistical and Data Analysis Center at Harvard School of Public Health, under the National Institute of Allergy and Infectious Diseases cooperative agreement No. 5 U01 AI41110 with the PACTG and No. 1 U01 AI068616 with the International Maternal Pediatric Adolescent AIDS Clinical Trials Group. Support of the sites was provided by the National Institute of Allergy and Infectious Diseases and the Eunice Kennedy Shriver National Institute of Child Health and Human Development; International and Domestic Pediatric and Maternal HIV Clinical Trials Network funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (contract number N01-DK-9-001/HHSN267200800001C).

The authors have no conflicts of interest to disclose.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Correspondence to: Denise L. Jacobson, PhD, MPH, Center for Biostatistics in AIDS Research, Harvard School of Public Health, 651 Huntington Avenue, Boston, MA 02115 (e-mail: jacobson@sdac.harvard.edu).

Copyright © 2011 by Lippincott Williams & Wilkins

raltegravir,²⁴ from zidovudine/lamivudine to tenofovir/emtricitabine²⁵ and from stavudine to tenofovir.²⁶ Children who switched from PI therapy to a PI-sparing regimen containing nevirapine showed mild decreases in total-C and increases in HDL-C²⁷ as did those who switched from PI to efavirenz.²⁸ More studies on the effect of switching ARV are needed in children as newer ARVs, such as atazanavir and darunavir that have an improved lipid profile, are approved in children older than 6 years.

Most perinatally infected children have not been followed long enough to determine the course and long-term consequences of sustained dyslipidemia or response to therapy. In the general population, the American Academy of Pediatrics recommends change in diet and engagement in physical activity as the first step to improve lipid measurements.²⁹ They recommend pharmacologic interventions for children with diabetes mellitus or when elevated LDL-C levels persist above a specified cutoff after dietary intervention fails to produce adequate improvement. Although several studies show efficacy of lipid-lowering agents in adults with HIV,^{30,31} the studies in HIV-infected children with dyslipidemia are ongoing and clearly needed to inform guidelines.

Clinical trials have investigated the association between specific ARVs and cholesterol levels in children, but little is known about the clinical management of hypercholesterolemia in practice. Tassiopoulos et al²⁰ reported an incidence rate of hypercholesterolemia of 3.4 per 100 person-years based on data from the Pediatric AIDS Clinical Trials Group (PACTG) 219C late outcomes study. In the present analysis, based on further follow-up of the same PACTG 219C cohort, we followed children after they developed hypercholesterolemia (1) to determine whether their cholesterol levels remained elevated over time, (2) to examine factors associated with reversion to normal cholesterol over 2 years of follow-up, and (3) to describe types of changes in ARV regimens and use of lipid-lowering medications. To our knowledge, this is the first study to describe the clinical course and management of hypercholesterolemia in HIV-infected children.

MATERIALS AND METHODS

Study Population

The PACTG 219C study is a prospective cohort study designed to examine long-term effects of HIV exposure and ART among HIV-infected and HIV-uninfected children born to HIV-infected women. Children were enrolled between September 2000 and March 2006 across 89 sites in the United States and Puerto Rico. The last follow-up visit occurred in May 2007. Children were examined at baseline and approximately every 3 months thereafter. At each visit, sociodemographic, clinical, and laboratory information were obtained, including clinical diagnoses, start and stop dates of ARV medications, use of concomitant medications, Centers for Disease Control and Prevention clinical classification, CD4⁺ T-lymphocyte count and percentage (cells/cubic millimeter, %), HIV viral loads (copies/milliliter), height (centimeters), weight (kilogram), blood pressure (absolute and percentiles), and other data not included in this analysis. Total cholesterol (milligrams/deciliter) was measured at each visit, although fasting was not required.

The institutional review board at each participating site approved the 219C protocol. Written informed consent was obtained from each child's parent/guardian or from older participants depending on age. Assent was obtained from children as appropriate. This analysis only includes perinatally HIV-infected children.

Definitions of Prevalent and Incident Hypercholesterolemia

We defined hypercholesterolemia as a cholesterol level of ≥ 220 mg/dL (rather than 200 mg/dL) to reduce misclassification, as fasting was not required. Children with *prevalent* hypercholesterolemia had a total cholesterol ≥ 220 mg/dL at the first visit in 219C at which cholesterol was measured. A child had *incident* hypercholesterolemia if the first measurement of total cholesterol in 219C was < 220 mg/dL and was followed by 2 consecutive 219C visits of cholesterol ≥ 220 mg/dL at any time during follow-up. Children with *no* hypercholesterolemia had cholesterol < 220 mg/dL at the first visit and did not have 2 consecutive visits with total cholesterol ≥ 220 mg/dL.

Inclusion and Exclusion Criteria

To study the evolution of cholesterol values after hypercholesterolemia, we only included children with at least 2 additional cholesterol measurements after prevalent or incident hypercholesterolemia and with at least 6 months of follow-up. Children with no hypercholesterolemia are not included in any analyses, except as a comparison group for describing use of cholesterol-lowering medications/supplements.

Variables Definitions

For the incident hypercholesterolemia group, *baseline* is the second cholesterol measurement of the pair that defined incident hypercholesterolemia. For the prevalent hypercholesterolemia group, *baseline* is the first cholesterol measurement in 219C. For the following variables, we used the baseline measurement as follows: age (< 10 , 10–12.9, ≥ 13 years), race/ethnicity (non-Hispanic black, Hispanic/white/other), body mass index (BMI) *z* score (> 1.96 vs. ≤ 1.96), CD4 percentage ($< 15\%$, 15–24.9%, $\geq 25\%$), and HIV viral load (< 400 , > 400 –5000, > 5000 copies/mL). Viral load and CD4 were within 30 days before or 7 days after the cholesterol measure. If BMI *z* score was missing, then the previous value was carried forward. We calculated percentiles for diastolic and systolic blood pressure for the age, sex, and height of the child based on population norms.³² The percentile for each of the blood pressure measurements was categorized as > 90 th percentile vs. ≤ 90 th percentile. From concomitant medications recorded for each child, we screened for statins, fibrates, bile acid sequestrants, niacin, and omega-3 fatty acid supplements. The first recorded date of use of a medication/supplement in each group was called the “initiation of use.” We defined reversion to normal cholesterol as 2 consecutive total cholesterol values < 200 mg/dL during follow-up among those with incident hypercholesterolemia.

Analysis

Baseline characteristics were described using the median (25th, 75th percentile) for continuous variables and *n* (%) for categorical variables. The median (25th, 75th) was computed

for cholesterol at 6-month intervals over the first 2 years of follow-up. To allow a window period at the 24-month visit after hypercholesterolemia, we included records up to 26 months. The percentage of children with reported use of lipid-lowering medications including statins, fibrates, and/or bile acid sequestrants was determined among those with (prevalent, incident) and without hypercholesterolemia. We determined the percentage of children who reported ARV at baseline and percentage who continued, discontinued, or initiated them at the end of 1 and 2 years after incident hypercholesterolemia relative to baseline use.

Time to Reversion of Cholesterol to Normal

We estimated median time to reversion to normal cholesterol over the first 2 years after incident hypercholesterolemia using a Kaplan–Meier survival estimate. Extended Cox models for time-dependent covariates were used to calculate crude hazard ratios and adjusted hazard ratios (aHR) for reversion to normal cholesterol over 2 years. Nonreverters were censored at their last visit (up to 26 months of follow-up). The primary predictors were time-varying covariates: (1) any change in ARV regimen and (2) class of ARV. For each child, we determined any change in ARV regimen. For children who changed regimen, we classified each visit before the regimen change as “no change” (value = 0) and the first visit with a changed regimen and all subsequent visits as “changed regimen” (value = 1). If the child did not change regimen, all visits were classified as “no change” (value = 0). At each visit, PI, NNRTI, nucleoside reverse transcriptase (NRTI), and others were categorized as “1” if taking and “0” if not taking medications in each. Use of statins or other lipid-lowering medications was not included as a predictor as too few children received them in the first 2 years of follow-up, and stop dates were ill defined. Confounders were included in adjusted models if they were independent predictors of the outcome at $P < 0.15$ or if the log hazard ratio of at least one of the main predictors changed more than 10% when the confounder was in the model. Potential confounders included race/ethnicity, baseline age, BMI, and blood pressure and time-varying covariates including CD4% and viral load at the previous visit.

RESULTS

Characteristics of Children at the Time of Development of Hypercholesterolemia

There were 2581 children with at least one cholesterol measurement. Of these, 342 had prevalent hypercholesterolemia, 282 had incident hypercholesterolemia, and 2239 had no hypercholesterolemia. Our analysis included 314 prevalent cases and 240 incident cases with at least 2 additional visits and at least 6 months of follow-up each. Among the 240 children with incident hypercholesterolemia, 218 (91%) had at least 1 year of follow-up, 213 (89%) had some follow-up in year 2, and 182 (76%) had at least 2 years of follow-up. Characteristics among those with prevalent and incident hypercholesterolemia are provided in Table 1. The median age was 8.7 years for the prevalent and 10.3 for the incident cases.

Approximately half of each group was male, and the majority was non-Hispanic black, similar to the characteristics of all enrolled subjects.²⁰ Median BMI z scores were slightly above the age- and sex-adjusted population average for the prevalent ($z = 0.34$) and incident ($z = 0.28$) cohorts. Systolic blood pressure was greater than the 90th percentile for 27% of the prevalent and 23% of the incident groups. HIV viral load was ≤ 400 copies per milliliter for 64% of the prevalent and 70% of

TABLE 1. Characteristics at the Time of Incident or Prevalent Hypercholesterolemia in HIV-Infected Children

Characteristics	Hypercholesterolemia	
	Prevalent (n = 314)	Incident (n = 240)
Age, y		
Median	8.7 (6.1–11.3)	10.3 (7.5–12.8)
Race/ethnicity, n (%)		
White non-Hispanic	61 (19)	39 (16)
Black non-Hispanic	170 (54)	129 (54)
Hispanic	79 (25)	69 (29)
Asian, Pacific Islander	1 (0)	1 (0)
Other/unknown	2 (1)	2 (1)
More than 1 race	1 (0)	0 (0)
Sex, n (%)		
Male	157 (50)	126 (53)
Female	157 (50)	114 (48)
BMI z score		
Median	0.34 (–0.31 to 0.95)	0.28 (–0.43 to 1.04)
Diastolic BP > 90th percentile		
Yes	32 (10)	11 (5)
No	261 (83)	206 (86)
Missing	21 (7)	23 (10)
Systolic BP > 90th percentile		
Yes	86 (27)	55 (23)
No	207 (66)	162 (68)
Missing	21 (7)	23 (10)
HIV RNA (copies/mL), n (%)		
0–400	201 (64)	169 (70)
401–5000	49 (16)	46 (17)
5001–50,000	28 (9)	14 (6)
>50,000	12 (4)	5 (2)
Missing	24 (8)	11 (5)
CD4%		
0–14	16 (5)	6 (3)
15–24	49 (15)	39 (16)
≥ 25	244 (78)	185 (77)
Missing	6 (2)	11 (5)
Cholesterol, mg/dL		
Median	242.5 (230–266)	236 (227–251)
ARV class, n (%)		
PI + NRTI (no NNRTI)	172 (55)	132 (55)
PI + NNRTI	119 (38)	90 (38)
NNRTI + NRTI	16 (5)	7 (3)
PI only	3 (1)	3 (1)
NRTI only	1 (0)	5 (2)
No ARV	3 (1)	3 (1)

BP, blood pressure.

TABLE 2. Initiation of Lipid-Lowering Medications/Supplements in Children With and Without Hypercholesterolemia

Medication or Supplement	Total n	Hypercholesterolemia				No High Cholesterol (n = 2239)‡
		Prevalent (n = 342)*		Incident (n = 282)†		
		Before Study Entry	After Study Entry	Before Event	After Event	
Statins	26	0	3	1	15§	7
Bile acid sequestrants	9	1	0	1	0	7
Fibrates	9	0	2	1	2	4
Niacin	2	0	0	0	1	1¶
Omega-3 fatty acids	3	0	2	0	0	1
Other medications	2	0	0	0	0	2#

These data represent the first reported date of use of each of these medications or supplements for each participant.

*All prevalent cases, regardless of duration of follow-up.

†All incident cases, regardless of duration of follow-up.

‡These children did not have prevalent or incident hypercholesterolemia by the definitions used in this study.

§One child was on statins, but the start date was not given. So, we assumed that statins were started after hypercholesterolemia.

||The child was on niacin tablets (nicotinic acid).

¶The child was on niacin as an antilipemic agent.

#One child was on clopidogrel bisulfate, and 1 child was on DH-581/probuocol.

TABLE 3. ARV Used in the First and Second Years of Follow-up Relative to Development of Incident Hypercholesterolemia

ARV Class	At Development of High Cholesterol	Period Relative to Development of Hypercholesterolemia			
		Within First Year (n = 240)*	n (%)	Within Second Year (n = 213)†	n (%)
PI	On PI	Remained on PI	221 (92.1)	Remained on PI	191 (90.1)
		Discontinued all PIs	4 (1.7)	Discontinued all PIs	10 (4.7)
	Not on PI	Not on PI	13 (5.4)	Not on PI	8 (3.8)
		Started PI	2 (0.8)	Started PI	3 (1.4)
NNRTI	On NNRTI	Remained on NNRTI	85 (35.4)	Remained on NNRTI	69 (32.4)
		Discontinued NNRTI	12 (5.0)	Discontinued NNRTI	18 (8.4)
	Not on NNRTI	Not on NNRTI	140 (58.3)	Not on NNRTI	120 (56.3)
		Started NNRTI	3 (1.2)	Started NNRTI	6 (2.8)
NRTI	On NRTI	Remained on NRTI	230 (95.8)	Remained on NRTI	201 (94.4)
		Discontinued NRTI	2 (0.8)	Discontinued NRTI	7 (3.3)
	Not on NRTI	Not on NRTI	7 (2.9)	Not on NRTI	4 (1.9)
		Started NRTI	1 (0.4)	Started NRTI	1 (0.5)
Specific ARV‡	Not on ATV	Started ATV	4/236	Started ATV	6/213
		On boosted PI	Switched to nonboosted	2/119	Switched to nonboosted
	On Specific PI	Switched to no PI	4/119	Switched to no PI	5/104
		Discontinued		Discontinued	
		Ritonavir or LPV/r	6/153	Ritonavir or LPV/r	11/136
		Amprenavir	2/10	Amprenavir	4/7
		Nelfinavir	6/72	Nelfinavir	11/66
		Indinavir	0/11	Indinavir	1/10
	On EFV	Saquinavir	1/14	Saquinavir	3/13
		Stopped EFV	10/53	Stopped EFV	13/48
	On EFV + PI	Switched from EFV to NVP	1/53	Switched from EFV to NVP	2/48
		On PI, dropped EFV	6/48	On PI, dropped EFV	8/44
	On d4T	Stopped d4T, started TDF or ABC	3/137	Stopped d4T, started TDF or ABC	5/123
	On ZDV	Stopped ZDV, started TDF or ABC	0/25	Stopped ZDV, started TDF or ABC	1/22
Not on TDF	Started TDF	5/227	Started TDF	18/195	

*Two hundred forty children had incident hypercholesterolemia.

†Twenty-seven of 240 had follow-up for less than 365 days after hypercholesterolemia and are not counted in the second year.

‡Switches presented are those associated with improvements in cholesterol cited in the literature.

ABC, abacavir; ATV, atazanavir; EFV, efavirenz; LPV/r, lopinavir/ritonavir; NVP, nevirapine; TDF, tenofovir; ZDV, zidovudine; d4T, stavudine.




FIGURE 1. Time to drop in total cholesterol below 200 mg/dL over 2 years of follow-up by age (years) at the time of hypercholesterolemia.

the incident groups. In addition, CD4% was $\geq 25\%$ among 78% and 77% of each group, respectively. Most children (93%) in each group were on a PI-based regimen. Differences in characteristics at the initial cholesterol measurement between those who did and did not develop incident hypercholesterolemia were reported by Tassiopoulos et al.²⁰

Use of statins, fibrates, bile acid sequestrants, and omega-3 fatty acids are provided in Table 2. Statins (n = 26) were used by more children than bile acid sequestrants (n = 9) and fibrates (n = 9). A few children reported use of niacin (n = 2), omega-3 fatty acids (n = 3), or other medications (n = 2). Three children with prevalent hypercholesterolemia started statins after entry into 219C (0.9%). Among those with incident hypercholesterolemia, 1 child (0.4%) started statins before hypercholesterolemia and 15 (5%) started statins after hypercholesterolemia (1 of whom had an unknown start date but was assumed to begin after). Seven of 2239 (<1%) children without hypercholesterolemia used statins sometime, all but one of whom began after their baseline cholesterol measure. The median time starting statins after incident hypercholesterolemia was 1.5 years (range, 0.5–4.5 years). Among 16 incident cases of hypercholesterolemia who used statins, 4 used atorvastatin only, 9 used pravastatin only, and 3 started with one of the above statins and then changed to the

other. Seven of 9 children who used bile acid sequestrants and 4 of 9 who used fibrates did not have hypercholesterolemia by our definition. One child began bile acid sequestrants and another began fibrates before incident hypercholesterolemia, and 2 children began fibrates after incident hypercholesterolemia. Evaluation of change in ARV regimen relative to use of lipid-lowering medications in the incident cohort revealed that 3 children changed their ARV regimen before and 3 changed after beginning statins and 1 changed regimen before and 1 after beginning fibrates. Among those who changed regimen before beginning a lipid-lowering medication, none had started atazanavir or darunavir.

ARV Regimen Changes After Developing Incident Hypercholesterolemia

In the first year after developing hypercholesterolemia, 204 children (85%) did not change their ARV regimen, 27 (11.2%) changed 1 time, 6 (2.5%) changed twice, and 3 (1.2%) changed 5 or more times (Table 3). Over 2 years, 64 children (27%) had at least 1 regimen change. At the end of the first and second years after incident hypercholesterolemia, 1.7% and 4.7% had discontinued PI, 5.0% and 8.4% had discontinued NNRTI, and 0.8% and 3.3% had discontinued NRTI, respectively. A few children began atazanavir as it was not labeled for pediatric use during this time. Four of the 6 who began atazanavir were also receiving ritonavir. Of note, for those followed for more than 1 year, 11 of 136 (8.1%) discontinued ritonavir or ritonavir/lopinavir and 13 of 48 (27%) discontinued efavirenz. A few children switched from stavudine or zidovudine to tenofovir or abacavir.

Reversion to Normal Cholesterol Level

Among the 240 children with incident hypercholesterolemia, 81 (34%) had resolution of their cholesterol to normal levels (<200 mg/dL on 2 consecutive visits) within 2 years of follow-up. Based on a Kaplan–Meier estimate, overall, approximately 20% of the 240 were estimated to fall below 200 mg/dL within the first year and 35% below 200 mg/dL after 2 years. Figure 1 shows the estimated time to reversion to normal cholesterol by age group at baseline among children with incident hypercholesterolemia. Children 13 years and older had a shorter time to reversion to normal cholesterol. Among the 314 in the prevalent cohort, 98 (31%) had a reversion of their cholesterol to normal levels (on 2 consecutive visits) where approximately 15% fell below 200 mg/dL within the first year and 29% after 2 years (not shown).

In Cox models, children 13 years and older [aHR = 2.4, 95% confidence interval (CI): 1.3 to 4.3] were more likely to revert to normal cholesterol over 2 years (Table 4) as were children who had any change in ARV regimen (aHR = 2.4, 95% CI: 1.5 to 3.9). The adjusted hazard ratio did not change with additional adjustment for viral load. However, children with viral load >5000 copies per milliliter were more likely to revert to normal cholesterol over 2 years (aHR = 2.7, 95% CI: 1.4 to 4.9). Class of ARV was not independently predictive of a drop in cholesterol to <200 mg/dL and not included in the adjusted models. In univariate models, children on efavirenz were less likely to have a reversion to normal cholesterol, whereas tenofovir users were more likely to drop to <200 mg/dL.

TABLE 4. Predictors of Reversion to Total Cholesterol to <200 mg/dL Within 2 Years After Incident Hypercholesterolemia

Characteristics	Adjusted Models					
	Unadjusted Models		Model 1 (Without RNA) (n = 226)		Model 2 (With RNA) (n = 217)*	
	HR (95% CI)	P	aHR (95% CI)	P	aHR (95% CI)	P
Change in ARV regimen (yes vs. no)	2.87 (1.79 to 4.59)	<0.001	2.37 (1.45 to 3.88)	<0.001	2.01 (1.21, 3.33)	0.01
Age, y		<0.001		0.01		0.02
≥13 vs. <10	3.07 (1.76 to 5.38)		2.39 (1.33 to 4.27)		2.31 (1.28 to 4.16)	
10–12 vs. <10	1.56 (0.87 to 2.80)		1.32 (0.73 to 2.39)		1.28 (0.70 to 2.35)	
HIV copies/mL (vs. ≤400)		<0.001				0.01
>5000	3.11 (1.70 to 5.69)	—	—	—	2.66 (1.42 to 4.90)	—
401–5000	1.62 (0.86 to 3.04)				1.44 (0.76 to 2.72)	
Male vs. female	0.92 (0.58 to 1.50)	0.72	—	—	—	—
Non-Hispanic black vs. Hispanic/white/other	0.96 (0.61 to 1.53)	0.88	—	—	—	—
Systolic BP > 90th percentile	0.86 (0.52 to 1.44)	0.58	—	—	—	—
Diastolic BP > 90th percentile	0.72 (0.29 to 1.80)	0.48	—	—	—	—
BMI z score > 1.96	0.56 (0.18 to 1.80)	0.33	—	—	—	—
CD4%†		0.11		—		—
<15 vs. >25	1.03 (0.14 to 7.45)		—		—	
15–24 vs. >25	1.89 (1.04 to 3.41)		—		—	
ARV class‡						
Current PI (yes vs. no)	0.81 (0.34 to 1.88)	0.62	—	—	—	—
Current NNRTI (yes vs. no)	0.55 (0.32 to 0.95)	0.03	—	—	—	—
Current NRTI (yes vs. no)	0.49 (0.18 to 1.29)	0.15	—	—	—	—

*The total number of children evaluated in this model is lower because some children did not have a viral load measure that was within 30 days before or 7 days after the cholesterol measure.

†This is a time-varying covariate.

‡Indicators for current PI, NNRTI, and NRTI use included together in the same model.

BP, blood pressure.

However, we had limited power to evaluate individual ARV agents in adjusted models, and thus, they are not presented. In a separate Cox regression analysis examining predictors of change in ARV regimen, those with detectable HIV viral load were 2.9 times (95% CI: 1.78 to 4.78, $P < 0.001$) more likely to change regimen but cholesterol level was not predictive of regimen change (aHR = 1.003, 95% CI: 0.998 to 1.008), $P = 0.30$), after adjustment for age.

Figure 2 shows the evolution of cholesterol levels over 2 years of follow-up by 6-month intervals. The median cholesterol level dropped from 236 mg/dL at the time of hypercholesterolemia to 217 mg/dL 6 months later. It was 220, 210, and 206 mg/dL at the 12-, 18-, and 24-month visit, respectively. Among children in our cohort who changed regimen, the average decrease in cholesterol was 22 mg/dL from the visit before regimen change until a median of 7 months after the regimen change.

DISCUSSION

The high prevalence¹⁰ and incidence of hypercholesterolemia²⁰ previously reported in this cohort of perinatally HIV-infected children and in other studies of children^{9–14} raises concern about the long-term risk of cardiovascular morbidity in HIV-infected children as they age into adulthood. There is a paucity of information on the course of hypercholesterolemia over time in HIV-infected children and the factors associated with

resolution of hypercholesterolemia. In this present analysis, the majority of children with incident hypercholesterolemia failed to demonstrate resolution of elevated cholesterol levels over 2 years of follow-up. The median cholesterol level decreased from 236 to 220 mg/dL in the first year, and only 20% of the children with incident hypercholesterolemia had a resolution to levels below 200 mg/dL within the first year and 35% by the second year of follow-up. Although guidelines exist for statin use in children without HIV²⁹ and studies are now ongoing on use of lipid-lowering medications in HIV-infected children, there are no published guidelines about what lipid levels should prompt pharmacologic intervention in HIV-infected children. As a likely consequence, only a small percentage of children initiated statins after developing hypercholesterolemia in our study, and the median time to initiation of treatment was 2.5 years after development of hypercholesterolemia.

Elevated total and LDL cholesterol and lower HDL cholesterol have been associated with PIs,^{10,13,15–19} especially ritonavir^{10,12,18}; NNRTIs¹⁰; and some NRTIs in HIV-infected children. Previous work in this cohort also found that children on PIs, boosted or nonboosted with ritonavir, were more likely to develop hypercholesterolemia.²⁰ As previously mentioned, numerous switch studies were performed in adults to evaluate whether lipid levels could be improved by substituting an ARV with a less atherogenic profile, whereas a few were done in children.^{21–28,33} To more fully understand management of hypercholesterolemia among HIV-infected children in this




FIGURE 2. Evolution of total cholesterol (milligrams/deciliter) within 2 years after incident hypercholesterolemia.

study, we evaluated types of changes in ARV regimens after incident hypercholesterolemia, focusing on changes that have been studied in clinical trials. Although any change in ARV therapy after incident hypercholesterolemia was associated with decline in cholesterol to normal values, regimen changes varied greatly from single to multiple drug substitutions, showing no distinct pattern. Twenty-seven percent of children with incident hypercholesterolemia made at least 1 change in their ARV regimen over 2 years, but a few children made the type of switches that were shown to be beneficial from clinical trials conducted in adults. Of all ARV regimen changes, the most prevalent was discontinuation of efavirenz.

Change in ARV regimen was associated with a decrease in cholesterol, but it is difficult to attribute the decrease to a specific class or agent in this cohort. We lacked power to detect differences in individual medications as changes in medication ranged from single substitutions to a complete change in regimen, and the majority of patients remained on PI. In addition to evaluating the types of changes in ARV, we also studied the magnitude of change in cholesterol after changing regimen. In studies where patients were switched to tenofovir, the magnitude of effect on total cholesterol ranged from a 4 to 18 mg/dL decrease.^{22,25,26} Among children in our cohort who changed regimen, the average change in cholesterol was 22 mg/dL. Although regimen change was associated with decreased cholesterol, our analysis of predictors of regimen change showed

that uncontrolled viral load and not hypercholesterolemia predicted change in ARV. High viral load may reflect non-adherence. Further studies are needed to understand the effect of specific regimen changes on cholesterol and to carefully control for the potential effects of disease severity, immune activation, and diet on cholesterol. In our cohort, children 13 years and older were more likely to revert to normal cholesterol. This may be partially explained by data from National Health and Nutrition Examination Survey, which showed that mean cholesterol levels peak at ages 9–11 and then decline in older children.³⁴ Children 13 years and older were also more likely to change ARV regimen, perhaps because they have more treatment options or are less adherent to ARV, as shown previously in the 219C cohort.³⁵ Poorer adherence could reduce exposure to deleterious effects of specific ARV, including hypercholesterolemia as shown by Tassiopoulos et al²⁰ in the examination of risk factors for developing hypercholesterolemia in the 219C cohort.

HIV-infected adults with dyslipidemia have benefited from statin use.^{30,31} Clinical trials of statins in infected children began after 219C was complete. This may explain why a few children in our cohort were known to have begun statin therapy after incident hypercholesterolemia. We were unable to determine the effect of statins on cholesterol levels as we did not have enough follow-up cholesterol values after children began statins. We also did not have enough information to determine how long statins were taken and if the children were adherent. Statin use was also reported by children with prevalent hypercholesterolemia and by children who did not fit our definition of hypercholesterolemia. In addition, other lipid-lowering medications were used by children in 219C to treat other types of dyslipidemia. However, we do not have information on fasting LDL or HDL cholesterol or triglycerides to determine if these lipid components were abnormal. The present guidelines for treating dyslipidemia recommend change in diet and increase in physical activity as first-line therapy,²⁹ which we did not collect, thus precluding assessment of compliance and benefit. Future studies will benefit from data on diet and exercise to better understand their effectiveness and provide recommendations and practice regarding dyslipidemia.

To our knowledge, a few studies have addressed management of children with hypercholesterolemia. We characterized clinical management of these children with available data and evaluated evolution of cholesterol over time and factors associated with resolution to normal levels. Future studies should monitor changes in LDL and HDL cholesterol and triglycerides over time in response to improvements in diet and exercise, newer ARV medications, and lipid-lowering medications. It is important to understand the long-term risk of cardiovascular disease among HIV-infected children as they progress to adulthood to develop safe preventive measures.

ACKNOWLEDGMENTS

We thank the children and families for their participation in PACTG 219C and the individuals and institutions involved in the conduct of 219C and the leadership and participants of the P219/219C protocol team. Overall support for the International Maternal Pediatric Adolescent AIDS Clinical Trials Group was

provided by the National Institute of Allergy and Infectious Diseases (U01 AI068632), the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health (AI068632). We also thank the individual staff members and sites who have participated in the conduct of this study, as provided in **Supplemental Digital Content 1** (see **Appendix**, <http://links.lww.com/QAI/A191>). We thank Todd Brown, MD, PhD, for clinical information used to develop this article.

REFERENCES

1. Grunfeld C, Pang M, Doerrler W, et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. *J Clin Endocrinol Metab*. 1992;74:1045–1052.
2. EL-Sadr WM, Mullin CM, Carr A, et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naïve cohort. *HIV Med*. 2005;6:114–121.
3. Constans J, Pellegrin JL, Peuchant E, et al. Plasma lipids in HIV-infected patients: a prospective study in 95 patients. *Eur J Clin Invest*. 1994;24:416–420.
4. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. *J Am Med Assoc*. 2003;289:2978–2982.
5. Grunfeld C, Kotler DP, Shigenaga JK, et al. Circulating interferon- α levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. *Am J Med*. 1991;90:154–162.
6. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. *AIDS*. 1998;12:F51–F58.
7. Mulligan K. Abnormalities of body composition and lipids associated with HAART: pathogenesis, clinical manifestations, and case definitions. Presented at: 7th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA, January 30–February 2, 2000. S20.
8. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. *J Acquir Immune Defic Syndr*. 2000;23:35–43.
9. Melvin AJ, Lennon S, Mohan KM, et al. Metabolic abnormalities in HIV type 1-infected children treated and not treated with protease inhibitors. *AIDS Res Hum Retroviruses*. 2001;17:1117–1123.
10. Farley J, Gona P, Crain M, et al. Prevalence of elevated cholesterol and associated risk factors among perinatally HIV-infected children (4–19 years old) in Pediatric AIDS Clinical Trials Group 219C. *J Acquir Immune Defic Syndr*. 2005;38:480–487.
11. Lainka E, Oezbek S, Falck M, et al. Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy. *Pediatrics*. 2002;110:e56.
12. European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. *AIDS*. 2004;18:1443–1451.
13. Bitnun A, Sochett E, Babyn P, et al. Serum lipids, glucose homeostasis and abdominal adipose tissue distribution in protease inhibitor-treated and naïve HIV-infected children. *AIDS*. 2003;17:1319–1327.
14. Rhoads MP, Smith CJ, Tudor-Williams G, et al. Effects of highly active antiretroviral therapy on paediatric metabolite levels. *HIV Med*. 2006;7:16–24.
15. Miller TL, Orav EJ, Lipshultz SE, et al. Risk factors for cardiovascular disease in children infected with human immunodeficiency virus-1. *J Pediatr*. 2008;153:491–497.
16. Carter RJ, Wiener J, Abrams EJ, et al. Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE cohort, 1999–2004: a longitudinal analysis. *J Acquir Immune Defic Syndr*. 2006;41:453–460.
17. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. *Circulation*. 1999;100:700–705.
18. Cheseaux JJ, Jotterand V, Aebi C, et al. Hyperlipidemia in HIV-infected children treated with protease inhibitors: relevance for cardiovascular diseases. *J Acquir Immune Defic Syndr*. 2002;30:288–293.
19. Chantry CJ, Hughes MD, Alvero C, et al. Lipid and glucose alterations in HIV-infected children beginning or changing antiretroviral therapy. *Pediatrics*. 2008;122:e129–e138.
20. Tassiopoulos K, Williams PL, Seage GR III, et al. Association of hypercholesterolemia incidence with antiretroviral treatment, including protease inhibitors, among perinatally HIV-infected children. *J Acquir Immune Defic Syndr*. 2008;47:607–614.
21. Flammer AJ, Vo NT, Ledergerber B, et al. Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: randomised controlled trial. *Heart*. 2009;95:385–390.
22. Sension M, Andrade Neto JL, Grinsztejn B, et al. Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir. *J Acquir Immune Defic Syndr*. 2009;51:153–162.
23. Colafigli M, Di Giambenedetto S, Bracciale L, et al. Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen. *HIV Med*. 2008;9:172–179.
24. Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. *Lancet*. 2010;375:396–407.
25. Fisher M, Moyle GJ, Shahmanesh M, et al. A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals. *J Acquir Immune Defic Syndr*. 2009;51:562–568.
26. Llibre JM, Domingo P, Palacios R, et al. Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir. *AIDS*. 2006;20:1407–1414.
27. Gonzalez-Tome MI, Amador JT, Pena MJ, et al. Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children. *BMC Infect Dis*. 2008;8:144.
28. McComsey G, Bhumbra N, Ma JF, et al. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study. *Pediatrics*. 2003;111:e275–e281.
29. Daniels SR, Greer FR, Committee on Nutrition. Lipid screening and cardiovascular health in childhood. *Pediatrics*. 2008;122:198–208.
30. Aberg JA, Zackin RA, Brobst SW, et al. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. *AIDS Res Hum Retroviruses*. 2005;21:757–767.
31. Calza L, Manfredi R, Colangeli V, et al. Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors. *Curr HIV Res*. 2008;6:572–578.
32. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. *Pediatrics*. 2004;114:555–576.
33. Vignano A, Aldrovandi GM, Giacomet V, et al. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children. *Antivir Ther*. 2005;10:917–924.
34. Hickman TB, Briefel RR, Carroll MD, et al. Distributions and trends of serum lipid levels among United States children and adolescents ages 4–19 years: data from the Third National Health and Nutrition Examination Survey. *Prev Med*. 1998;27:879–890.
35. Williams PL, Storm D, Montepiedra G, et al. Predictors of adherence to antiretroviral medications in children and adolescents with HIV infection. *Pediatrics*. 2006;118:e1745–e1757.